Please sign in to follow a disease.
Can a Patient's own immune cells be trained to cure leukemia?
NCT ID NCT02028455
First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time
Summary
This trial tests a personalized therapy where a patient's own T cells are collected, genetically modified to recognize and attack CD19-positive leukemia cells, and then infused back into the patient. It is designed for children and young adults with relapsed or refractory CD19+ acute leukemia, including those who have already had a stem cell transplant. The study aims to determine the safest dose and whether this treatment can achieve a complete remission with no detectable disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Patient-derived CD19-specific CAR T cells (engineered immune cells)
- What this could lead to
- If successful, this approach could offer a durable remission or even a cure for children and young adults with relapsed or refractory CD19+ leukemia, potentially replacing the need for further chemotherapy or transplant.
- What could go wrong
- This is an early-phase trial, so the treatment may not work for everyone and could cause severe side effects, including cytokine release syndrome or neurological toxicity. The long-term durability of remission is still unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CD19+ ACUTE LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Children's Hospital Los Angeles
Los Angeles, California, 90027, United States
-
Children's Hospital Oakland
Oakland, California, 94609, United States
-
Seattle Children's Hospital
Seattle, Washington, 98105, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.